Imatinib (IM) is a tyrosine–kinase inhibitor (TKI) that inhibits the BCR-ABL1 protein in Ph-positive CML [4]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.